

Moving Out

90% of Patient deaths are due to non-primary tumors

- Size of all tumors are difficult to detect
 - Brain vs peritoneal/pleural space
- Compromising vital functions – block passage of product, lung function, bone break
- Seed and soil – metastasis form micrometastasis in distal sites, fertile ground allows tumors to thrive
 - Breast -> brain, liver bones and lungs
 - Colon -> liver
 - Prostate -> bones

F deoxyglucose labeling of metabolically active tissue – brain and tumors – highlighting metastatic disease from non-Hodgkin's lymphoma

Which View?

The Reductionist View

- Historical bias of cancer – homogeneous tumor cells break free from basal membrane to form metastasis

A Heterotypic Cell Biology

- Tumors are complex tissues: conscription of normal stromal and inflammation cells to act as collaborators of neoplastic programming.

Cancer Staging

Staging is used to determine the severity of the cancer – use TMN staging system

- Tumor – size extent and location (0-4)
- Nodes – lymph node involvement (0-3)
- Metastasis – Presence or absence of distant metastasis (0 or 1)

Primary Tumor (T)	TX	Tumor cannot be evaluated
	T0	No evidence of primary tumor
	Tis	Carcinoma in situ (early cancer that has not spread locally)
	T1, T2, T3, T4	Size and/or extent of tumor
Regional Lymph Nodes (N)	NX	Nodes cannot be evaluated
	N0	No nodal involvement
	N1, N2, N3	Nodal involvement (number/extent of spread)
Distant Metastasis (M)	MX	Cannot be evaluated
	M0	No evidence of metastasis
	M1	Metastasis

A number may be added to each letter to indicate size or spread of tumor

A T3N2M0 tumor is large, with local nodes but no evidence of metastasis

- Most cancers can be assigned TNM classification. CNS tumours are classified according to cell type and grade, lymphomas have a different staging system and hematological malignancies are considered differently again.
- For many cancers, TNM designations correspond to one of five stages. Criteria for stages differ for different types of cancer. For example in bladder cancer T3 N0 M0 is stage III; however, in colon cancer T3 N0 M0 is stage II.

Stage	Definition
Stage 0	Carcinoma in situ (early cancer that is present only in the layer of cells in which it began)
Stage I	
Stage II	Higher numbers indicate more extensive disease: greater tumor size, and/or spread of the cancer to nearby lymph nodes and/or organs adjacent to the primary tumor
Stage III	
Stage IV	The cancer has spread to another organ.

Examples

normal skin

hyperplasia

dysplasia

prostate cancer (PIN, in situ)

invasive prostate cancer

human breast cancer (in situ)

invasive human breast cancer

Figure 13.48 The Biology of Cancer © Garland Science 2016

Invasion – Metastasis Cascade

- 80% of most aggressive cancers occur in epithelial cells yielding carcinomas.
- Carcinomas begin on epithelial side of BM and are benign until they breach BM
- BM = Extra cellular matrix – produced by fibroblasts and stromal cells
- Once crossing BM cells are malignant

Invasion and Metastasis: Breaching the BM

- Angiogenesis begins before BM is degraded
- But once invading through BM carcinomas gain access to stromal cells, agonists and better involvement with blood vessels and lymphatic system
- Loss of BM can predict future course of metastatic disease

High grade carcinomas T3 and correlation with BM loss. Survival after surgical removal of primary tumor

A) Less aggressive/differentiated colorectal carcinoma islands (red anti cytokeratin Ab) and BM (green laminin Ab). Stromal cells are not labeled (black)

B) Less differentiated aggressive carcinoma staining – arrows highlight loss of BM and stromal/carcinoma interaction

Intravasation

- Primary cancer cells entering the blood (or lymph) system is Intravasation.

Crossing the endothelial barrier during metastasis
Nicolas Raymond, Bárbara Borde d'Água & Anne J. Ridley
Nature Reviews Cancer 13, 858–870 (2013) doi:10.1038/nrc3628

- After invasion through BM and stromal cells, cancer cells enter by remodeling endothelial lining of blood vessel – between or through cells
- Proteases degrade cadherin and gap junctions inducing cell retraction
- Actin contraction is stimulated by MLC kinase and calcium calmodulin signaling

Rough Travels

- Lack of contact (many tumor cells maintain some requirement), loss of stromal cell factors, shear factors and size of vessels (cancer cells > 20µM while capillaries ~3-8µM) create hostile environment for most escaping tumor cells
- Most cells die by anoikis (form of apoptosis)
- Circulating tumor cells often become trapped in lungs – but many do not stay as they find through to tissue capillaries or move within tissues
- Complicating passage is many tumor cells recruit and macrophages/platelets – found as multicellular aggregate

Time to leave - Extravasation

- Several mechanisms – different than leukocytes (can travel between endothelial cells by a process called diapedesis)
 - Use a similar mechanism as intravasation
 - Can proliferate to obliterate adjacent vessel wall.
 - Helped by macrophages recruited while reroute

Trapped cells (cancer and platelets) form microthrombus. Protease and mechanical reduction of endothelial cells leave capillary BM to invade. Proliferation within the lumen allows invasion into surrounding parenchyma tissue

- Receptor mediated attachment of cancer cell to endothelial cells induce small G proteins (Ras, Rac, Rho) to re-arrange cancer cell shape and allow protrusion and tail retraction
- Receptors also induce expression and secretion of factors (integrin) and proteases to allow for junction disassembly of endothelial cells.

- Cancer cell interaction with platelets protect tumor cells against immune lysis by natural/hunter killer cells.
- Platelets secrete factors and help recruit neutrophils which secrete pro-inflammatory cytokines and help adhesion.
- Cancer cells help the process by release of cytokines which drive endothelial retraction and extravasation by VEGF and other factors

Epithelial-Mesenchyme Transition (EMT) is part of maturation as cancer cells begin before/ during intravasation

- Epithelial cells are highly attached to neighboring cells (via gap junctions and E cadherin) and are poorly motile. Shift from epithelial to fibroblast appearance and acquire many new mesenchymal phenotypes

Loss of
Cytokeratin (intermediate filament) expression
Tight junctions and epithelial adherens junctions involving E-cadherin
Epithelial cell polarity
Epithelial gene expression program
Acquisition of
Fibroblast-like shape
Motility
Invasiveness
Increased resistance to apoptosis
Mesenchymal gene expression program including EMT-inducing transcription factors
Mesenchymal adherens junction proteins (E-cadherin)
Protease secretion (MMP-2, MMP-9)
Vimentin (intermediate filament) expression
Fibronectin secretion
PDGF receptor expression
α _v β ₃ integrin expression
Stem cell-like traits

Driving Miss Daisy






- Cancer genomes are typically altered at multiple points (hundreds) in a single tumor
- Key somatic mutations which significantly contribute to tumor progression are “Driver Mutations” Confer growth advantage and positive selection in microenvironment
- “Passenger or Neutral Mutations” may not help tumor formation and progression and are simply carried along and the result of mutational environment (lack of repair...)
- EMT Drivers include transcription factors altering E-cadherin. (Snail, Slug, Zeb1 and Twist) and E cadherin itself


Table 14.3 Transcription factors orchestrating an EMT

Name	Where first identified	Type of transcription factor	Cancer association
Snail (SNAI1)	mesoderm induction in <i>Drosophila</i> ; neural crest migration in vertebrates	C2H2-type zinc finger	invasive ductal carcinoma
Slug (SNAI2)	delamination of the neural crest and early mesoderm in chicken	C2H2-type zinc finger	breast cancer cell lines, melanoma
Twist	mesoderm induction in <i>Drosophila</i> ; emigration from neural crest	bHLH	various carcinomas, high-grade melanoma, neuroblastoma
Goosecoid	gastrulation in frog	paired homeodomain	various carcinomas
FOXO2	mesenchyme formation	winged helix/forkhead	basal-like breast cancer
ZEB1 (6EF1)	postgastrulation mesodermal tissue formation	2-handed zinc finger/homeodomain	wide variety of cancers
ZEB2 (SIP1)	neurogenesis	2-handed zinc finger/homeodomain	ovarian, breast, liver carcinomas
E12/E47 (Tcf3) ^a	associated with E-cadherin promoter	bHLH	gastric cancer

It remains unclear whether E12/E47 can function on its own to induce an EMT, or whether this bHLH functions as a subunit of a heterodimeric TF complex formed with other well-validated EMT-TF proteins such as Twist.


Table 14.3 The Biology of Cancer © Garland Science 2014





Colonization – the new beginning

- Micrometastases – colonization by small clumps of metastasizing cancer (and associated) cells
- Most foreign tissues do not contain proper mix of stromal cells/signaling factors for continued proliferation
- > 30% of breast cancer patients harbor 100-1000s of micrometastases but only half will show development of these metastatic nascent tumors
- In mice primary tumors ($1g \sim 10^9$ cells) seed more than 1 mil cells per day into blood/lymph but less than 5 will survive to form metastasis.



Proteases and Invasion/Metastasis